RFS2000 (9-nitrocamptothecin) in advanced small cell lung cancer, a phase II study of the EORTC New Drug Development Group

European Journal of Cancer

Volumn 40, Issue 9, 2004, Pages 1332-1334

  Punt, C J A ^a   De Jonge, M J A ^b   Monfardini, S ^c   Daugaard, G ^d   Fiedler, W ^e   Baron, B ^f   Lacombe, D ^f   Fumoleau, P ^g  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^d Rigshospitalet   (Denmark)

^e UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^f EORTC DATA CENTER   (Belgium)

^g CENTRE RENÉ GAUDUCHEAU   (France)

Author keywords

Chemotherapy; EORTC; Phase II study; RFS2000; Rubitecan; Small cell lung cancer

Indexed keywords

RUBITECAN;

ADULT; AGED; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; EVALUATION; FEBRILE NEUTROPENIA; HUMAN; LUNG SMALL CELL CANCER; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

AGED; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CARCINOMA, SMALL CELL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; TREATMENT FAILURE;

EID: 2942574452     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2004.02.016     Document Type: Article

References (14)

1. Masuda N., Masahiro F., Kusunoki Y., et al. CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J. Clin. Oncol. 10:1992;1225-1229
2. Ardizzoni A., Hansen H., Dombernowsky P., et al. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug development Office, and the Lung Cancer Cooperative Group. J. Clin. Oncol. 15:1997;2090-2096
3. Schiller J.H., Adak S., Cella D., DeVore R.F. III, Johnson D.H. Topotecan versus observation after cisplatin plus etoposide in extensive-stage small cell lung cancer: E7593 - a phase III trial of the Eastern Cooperative Oncology Group. J. Clin. Oncol. 19:2001;2114-2122
4. Jaxel C., Kohn K.W., Wani M.C., Wall M.C., Pommier Y. Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity. Cancer Res. 49:1989;1465-1469
5. Rubin E., Pantazis P., Bharti A., Toppmeyer D., Giovanella B., Kufe D. Identification of a mutant human topoisomerase I with intact catalytic activity and resistance to 9-nitrocamptothecin. J. Biol. Chem. 269:1994;2433-2439
6. Tanizawa A., Beirtrand R., Kohlhagen G., Tabuchi A., Jenkins J., Pommier Y. Cloning of Chinese hamster DNA topoisomerase I cDNA and identification of a single point mutation responsible for camptothecin resistance. J. Biol. Chem. 268:1993;25463-25468
7. Pantazis P. Preclinical studies of water-insoluble camptothecin congeners: cytotoxicity, development of resistance, and combination treatments. Clin. Cancer Res. 1:1995;1235-1244
8. Verschraegen C.F., Natelson E.A., Giovanella B.C., et al. A phase I clinical and pharmacological study of oral 9-nitrocamptothecin, a novel water-insoluble topoisomerase I inhibitor. Anticancer Drug. 9:1998;36-44
9. Schöffski P., Herr A., Vermorken J.B., et al. Clinical phase II study and pharmacological evaluation of rubitecan in non-pretreated patients with metastatic colorectal cancer - significant effect of food intake on the bioavailability of the oral camptothecin analogue. Eur. J. Cancer. 38:2002;807-813
10. Konstadoulakis M.M., Antonakis P.T., Tsibloulis B.G., et al. A phase II study of 9-nitrocamptothecin in patients with advanced pancreatic adenocarcinoma. Cancer Chemother. Pharmacol. 48:2001;417-420
11. Raymond E., Campone M., Stupp R., et al. Multicentre phase II and pharmacokinetic study of RFS2000 (9-nitrocamptothecin) administered orally 5 days a week in patients with glioblastoma multiforme. Eur. J. Cancer. 38:2002;1348-1350
12. Patel S.R., Beach J., Papadopoulos N., et al. Results of a 2-arm phase II study of 9-nitrocamptothecin in patients with advanced soft-tissue sarcomas. Cancer. 97:2003;2848-2852
13. Ellerhorst J.A., Bedikian A.Y., Smith T.M., Papadopoulos N.E., Plager C., Eton O. Phase II trial of 9-nitrocamptothecin (RFS2000) for patients with metastatic cutaneous or uveal melanoma. Anticancer Drug. 13:2002;169-172
14. Verschraegen C.F., Gupta E., Loyer E., et al. A phase II clinical and pharmacological study of oral 9-nitrocamptothecin in patients with refractory epithelial ovarian, tubal or peritoneal cancer. Anticancer Drug. 10:1999;375-383